Outlook Share Price

Outlook Share Price

NASDAQ: OTLK | Micro Cap | Healthcare
$0.39
-$0.02 (-5.05%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Outlook Stock Performance

Open
$0.39
Prev. Close
$0.41
Circuit Range
N/A
Day Range
$0.36 - $0.40
Year Range
$0.16 - $2.51
Volume
81,017
Average Traded
$0.37

Outlook Share Price Today

As of 21 November 2026, Outlook Therapeutics, Inc.'s share price is $0.39. The stock opened at $0.39, compared to its previous close of $0.41. During today's trading session, Outlook Therapeutics, Inc.'s share price traded between $0.36 and $0.40, with an average price of $0.38. Over the past 52 weeks, the stock has recorded a high of $2.51 and a low of $0.16. In terms of performance, Outlook Therapeutics, Inc.'s share price has declined by 47.09% over the last six months and is down 78.51% on a year-on-year basis.

Outlook Share Price Chart

Line chart of the Outlook price trend over the selected period. The price fell overall, ranging from 0.36 to 0.40, ending at 0.39.
$0.36$0.40
L
Show Current Price
H

Outlook Stock Fundamentals & Key Indicators

Market Cap
$13.42M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.20
Revenue (TTM)
$1.41B
Return On Equity (TTM)
460.24%
Profit Margin
-4426.95%
Debt to Equity
-1.75
Quarterly Earnings Growth YoY
N/A

Outlook Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
RevenueN/A-$1.21$0.13$0.01
Net ProfitN/A-$23.06-$4.45-$20.32
Net Profit MarginN/A1905.79%-3423.08%-203200.00%
Income ChangeN/AN/A80.70%-356.63%

Outlook Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$1.41
Net Profit-$66.05-$58.98-$75.37-$62.42
Net Profit MarginN/AN/AN/A-4426.95%
Income ChangeN/A10.70%-27.79%17.18%

Outlook Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets1.21.411.321.01
Current Assets17.3927.4230.9827.52
Total Assets18.5828.8232.328.53
Non Current Liabilities4.9659.350.00.0
Current Liabilities45.8142.5546.7319.73
Total Liabilities50.77101.946.7319.73
Shareholders' Equity-32.19-73.08-14.438.79

Outlook Cash Flow

Annually
Particulars2025202420232022
Operating (USD Million)-51.83-68.79-42.97-56.67
Investing (USD Billion)0.00.00.00.0
Financing (USD Million)44.9860.3348.9759.59

Corporate Actions

Split
Ex-date: 14 Mar 2024

Split
Ex-date: 18 Mar 2019

About Outlook

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.46
$0.39
-17.17%
Oct 2026
$0.56
$0.47
-19.52%
Sep 2026
$0.63
$0.58
-9.67%
Aug 2026
$0.94
$0.64
-34.46%
Jul 2026
$1.49
$0.98
-38.88%
Jun 2026
$0.74
$1.60
+119.48%
May 2026
$0.26
$0.73
+188.14%
Apr 2026
$0.21
$0.25
+25.87%
Mar 2026
$0.43
$0.20
-52.48%
Feb 2026
$0.43
$0.42
-3.20%
Jan 2026
$0.64
$0.44
-72.34%
Dec 2025
$1.79
$1.58
-11.98%

Outlook Share Price FAQs